NASDAQ:ACAD - Nasdaq - US0042251084 - Common Stock - Currency: USD
ACAD gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 557 industry peers in the Biotechnology industry. While ACAD has a great health rating, its profitability is only average at the moment. ACAD is not overvalued while it is showing excellent growth. This is an interesting combination. With these ratings, ACAD could be worth investigating further for growth investing!.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 20.23% | ||
ROE | 29.93% | ||
ROIC | 9.3% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 8.84% | ||
PM (TTM) | 22.99% | ||
GM | 92.08% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | 0 | ||
Altman-Z | 4.75 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.87 | ||
Quick Ratio | 2.8 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 42.61 | ||
Fwd PE | 23.65 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 70.62 | ||
EV/EBITDA | 35.45 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
20.88
-0.07 (-0.33%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 42.61 | ||
Fwd PE | 23.65 | ||
P/S | 3.51 | ||
P/FCF | 70.62 | ||
P/OCF | 23.45 | ||
P/B | 4.57 | ||
P/tB | 5.39 | ||
EV/EBITDA | 35.45 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 20.23% | ||
ROE | 29.93% | ||
ROCE | 10.62% | ||
ROIC | 9.3% | ||
ROICexc | 9.3% | ||
ROICexgc | 10.83% | ||
OM | 8.84% | ||
PM (TTM) | 22.99% | ||
GM | 92.08% | ||
FCFM | 4.97% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | 0 | ||
Debt/EBITDA | 0 | ||
Cap/Depr | N/A | ||
Cap/Sales | N/A | ||
Interest Coverage | 250 | ||
Cash Conversion | 151.14% | ||
Profit Quality | 21.61% | ||
Current Ratio | 2.87 | ||
Quick Ratio | 2.8 | ||
Altman-Z | 4.75 |